Analytical Data
-
Gene name
CC16
- Application
-
Alternative Names
CC16；ANAPC6；Cell division cycle Protein 16 homolog
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11684
-
Expression Region
22-91aa
-
AA Sequence
EICPSFQRVI ETLLMDTPSS YEAAMELFSP DQDMREAGAQ LKKLVDTLPQ KPRESIIKLM EKIAQSSLCN
-
Molecular Weight
7.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CC16, also known as Clara Cell Protein 16, is a lung-specific protein predominantly secreted by Clara cells in the airway epithelium. It plays a crucial role in pulmonary function and has been implicated in various respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. Research into CC16 has gained momentum due to its potential as a biomarker for lung health and disease. Elevated or decreased levels of CC16 in serum or bronchoalveolar lavage fluid can indicate inflammatory processes or damage to the airways. Studies have shown that CC16 possesses anti-inflammatory and antioxidant properties, suggesting its protective role against airway injury. Moreover, CC16 has been explored as a therapeutic target, with the aim of modulating its levels to ameliorate lung diseases. Recent advancements in recombinant technology have enabled the production of CC16 as a recombinant protein, facilitating more detailed studies on its biological functions and mechanisms. These studies are crucial for understanding the pathophysiology of lung diseases and developing novel diagnostic and therapeutic strategies. Investigating CC16's structure, function, and interactions at the molecular level is essential to unlocking its potential in clinical applications and enhancing lung disease management.
